Activated protein C for sepsis: Can protein C levels guide therapy?
Evidence which has accumulated since the original approval of activated protein C for severe sepsis suggests that patient selection is more difficult than originally anticipated. Patients with lower levels of endogenous protein C have worse outcomes in sepsis and might stand to benefit more from treatment. Could measurement of endogenous levels help select patients and guide treatment? RESPOND, a phase II study, aims to find out.